| Acute Leukemia Follow-up Panel | 17821X |
|
 |
||
| Initial markers evaluated: CD3, CD7, CD13, CD19, CD20, CD33, CD34, CD45, CD64. CD45 is used for gating.This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. Additional markers may be performed based on the pathologist review. These markers will be performed at an additional charge (CPT code(s): 88185 for each additional marker). | ||
| CPT Code(s): 88184; 88185 (x8); 88188 | Clinical Significance: To aid in the follow-up of a known acute leukemia. |
|
| Specimen Container: Sodium heparin (green-top) |
| Preferred Specimen: 3 mL whole blood |
| Instructions: A clinical summary or differential diagnosis is required with each specimen. If possible, submit CBC results with differential or an EDTA tube of peripheral blood. Ship immediately. |
| Transport Temperaturer: Room temperature, stable 3 days |
| Methodology: Flow Cytometry |
